Stelios Papadopoulos, at the summit of a career spanning most of biotech's recorded history, faces a challenge that will color his legacy. ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

Sponsored by      For the ‘godfather’ of biotech, saving Biogen is the final act of a singular career By Damian Garde Mike Reddy for STAT In the history of the global pharmaceutical industry, there have been many big thinkers, brash visionaries, and billionaire disruptors. But there has only ever been one Godfather. Stelios Papadopoulos, 74, has spent the past four decades becoming the living embodiment of biotech’s institutional memory. Now, Papadopoulos faces a challenge that will color his legacy. As chairman of the board at Biogen, the industry veteran is charged with turning the storied company around over the course of what will be a decisive year. Read More Sponsor content by PANDEMIC RESPONSE LAB How can syndromic PCR panels advance infectious disease and routine health screening? Traditional diagnostics targeting a single pathogen requires serial testing to identify infections, which can lead to delayed diagnosis, blanket use of antibiotics, and increased healthcare costs. Recent advancements in multiplex PCR technology—used to detect respiratory co-infections, sexually transmitted infections, and more—can optimize turnaround time, cost-efficiency, and treatment plans while increasing patient satisfaction and minimizing the spread of infections. Learn more about the benefits of syndromic PCR panels.  More great reads from STAT this week 10 key questions about monkeypox the world needs to answer By Megan Molteni, Helen Branswell, Andrew Joseph, and Jason Mast A third Covid autumn is upon us. Here’s a look at where we stand By J. Emory Parker and Andrew Joseph Your questions on the new Covid vaccine boosters answered By Helen Branswell, Matthew Herper, and Sarah Owermohle Once a small player among biotech VCs, Mubadala Capital Ventures is punching above its weight By Allison DeAngelis Fed up with costly, onerous recertification, doctors are turning to an alternative board By Tara Bannow Opinion: ‘Whose life do I prioritize?’ A choice no parent wants to make By Christopher Hartnick The Biden administration is pushing another round of Covid boosters. Who’s listening? By Sarah Owermohle A Q&A with WHO’s Maria Van Kerkhove on Covid — and fatigue over the pandemic By Helen Branswell Saturday, September 3, 2022       1 Exchange Pl, Suite 201, Boston, MA 02109 ©2022, All Rights Reserved. I no longer wish to receive STAT emails Update Email Preferences | Contact Us | View In Browser